为解决 PARP 抑制剂（PARPi）耐药问题，研究人员开展相关研究，发现 ARL11 和 RUVBL1/2 或可增敏乳腺癌细胞对 PARPi 治疗。 聚（ADP - 核糖）聚合酶抑制剂（PARPi）耐药在临床实践中仍是重大难题，导致许多患者治疗失败。深入了解 PARPi 耐药的分子机制至关重要。

Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.

Other PARP inhibitors have validated the mechanism ... IDX-1197 is likely to be used in various types of combination therapy. Researchers have demonstrated the potency of IDX-1197 in in vitro ...

Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments because they block a cell’s ability to repair DNA damage. Four PARPis are currently approved for use in the ...

In 2005, researchers in the U.K. struck upon a new way to kill cancer cells. A London-based team led by Alan Ashworth, currently head of the University of California, San Francisco’s cancer center, ...

The study was published March 26 in the journal Nature. Yet scientists have struggled to understand how it is that PARP inhibitors kill cancer cells in these patients and why this treatment usually ...

Evaluate notes that further data on the role of combined PD-1/PD-L1 and PARP inhibitor therapy as first-line maintenance therapy for advanced ovarian cancer will come from the Keylynk-001 study of ...

A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.